Información de la revista
Vol. 115. Núm. 9.
Páginas T917 (octubre 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 115. Núm. 9.
Páginas T917 (octubre 2024)
Images in Dermatology
Acceso a texto completo
Myeloid Sarcoma After «Complete» Remission of Acute Myeloid Leukemia
Sarcoma mieloide tras remisión «completa» de leucemia mieloide aguda
Visitas
1211
F.J. Rodríguez-Cuadradoa,
Autor para correspondencia
, G. Silvestre-Egeab, I. Salgüero-Fernándeza
a Servicio de Dermatología, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain
b Servicio de Anatomía Patológica, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain
Contenido relacionado
Actas Dermosifiliogr. 2024;115:91710.1016/j.ad.2023.05.037
F.J. Rodríguez-Cuadrado, G. Silvestre-Egea, I. Salgüero-Fernández
Este artículo ha recibido
Información del artículo
Texto completo
Descargar PDF
Estadísticas
Figuras (2)
Texto completo

An 87-year-old woman presented with a 1-year old lesion on her left leg. The patient had a history of acute myeloid leukemia with trilineage dysplasia and BCR-ABL p1.90 mutation, for which she received chemotherapy until complete remission 18 years earlier. Physical examination revealed the presence of a 17cm×13cm hyperkeratotic plaque of a yellowish-brown color with papillomatous projections of a villous appearance, on a highly infiltrated 21cm×16.5cm erythematous-squamous base (Fig. 1).

Figure 1
(0.07MB).

Biopsy of the lesion confirmed the dermal infiltration of polygonal eosinophilic cells with an elevated number of mitoses, pleomorphic nuclei, and karyorrhexis (Fig. 2A and 2B). Immunohistochemistry tested positive for CD123 (a marker for malignant hematologic neoplasms, including plasmacytoid dendritic cell neoplasm or acute myeloid leukemia) (Fig. 2C), and for CD43, CD45, CD99, CD117, and Bcl-2. Molecular study showed a mutated/non-mutated FLT3 ratio of 0.78; a pathogenic mutation in exon 12 of NPM1; and expression of the WT1 gene, without identification of the BCR-ABL mutation. These findings led to a diagnosis of myeloid sarcoma associated with the previous myeloproliferative process.

Figure 2
(0.17MB).

The patient was treated with radiotherapy (1st cycle of 4Gy fractionated in 2 sessions and 2nd cycle of 20Gy fractionated in 10 sessions) and chemotherapy (8 cycles of azacitidine 100mg every 24h for 7 days per cycle and midostaurin 50mg every 12h). Two years after diagnosis, the patient was still very responsive to therapy.

Copyright © 2023. AEDV
Descargar PDF
Idiomas
Actas Dermo-Sifiliográficas
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?